IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination

Hongchang Shen1, Yan Fang, Wei Dong

  • 1Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan 250021, China.

FEBS Open Bio
|May 8, 2013
PubMed

Insights

Sunitinib inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling and promotes its degradation via ubiquitination, involving MDM2. This highlights sunitinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Insulin-like growth factor-1 receptor (IGF-1R) is crucial in cancer development.
  • Understanding IGF-1R signaling is vital for targeted cancer therapies.

Purpose of the Study:

  • To investigate sunitinib's effects on IGF-1R signaling pathways.
  • To analyze sunitinib's impact on IGF-1R phosphorylation and ubiquitination.

Main Methods:

  • HEK293 cells were used to study IGF-1R signaling.
  • Cells were treated with IGF-1 and sunitinib to assess phosphorylation (Akt, ERK) and expression.
  • Ubiquitination was analyzed after IGF-1 or sunitinib stimulation, with and without MDM2 manipulation.

Main Results:

  • Sunitinib significantly inhibited IGF-1-induced phosphorylation of IGF-1R, Akt, and ERK.
  • Both IGF-1 and sunitinib down-regulated IGF-1R expression and increased its ubiquitination.
  • Sunitinib-induced IGF-1R ubiquitination was dependent on MDM2, promoting receptor degradation.

Conclusions:

  • Sunitinib effectively blocks IGF-1R signaling transduction.
  • Sunitinib mediates IGF-1R degradation through an MDM2-dependent ubiquitination pathway.
  • These findings offer insights into sunitinib's anti-cancer mechanisms via IGF-1R modulation.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...